Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 3 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Misdiagnosis of early gastric cancer characteristics, type leads to overtreatment

19 Nov 2019

Tumour diameter, depth and histological type are correlated with overtreatment with surgery in patients with early gastric cancer (EGC), a recent study has found.

Researchers performed a retrospective analysis of 781 EGC patients (median age, 68 years; 72.5 percent male) who were treated with surgical resection. Postoperative outcomes were used to determine whether patients indeed needed surgery or were overtreated. Predictive factors assessed included tumour diameter, depth, ulcerative diagnoses and main histology.

More than a quarter were identified to have been overtreated (28.7 percent; n=224). Almost half of the patients were misdiagnosed in terms of ulcerative findings (49.6 percent) and depth (40.7 percent). Misdiagnosis of histological type (14.7 percent) and tumour diameter (5.1 percent) were much rarer.

Comparison according to treatment appropriateness showed that misdiagnosis of tumour diameter (14.7 percent vs 1.3 percent), depth (75.9 percent vs 26.6 percent) and main cancer histology (24.1 percent vs 11.0 percent) were all significantly over-represented in patients who were overtreated with surgery.

These were confirmed in multivariate analysis. Misdiagnosis of tumour diameter (odds ratio [OR], 19.8, 95 percent confidence intervals [CI], 7.5–52.2; p<0.0001), depth (OR, 15.0, 95 percent CI, 9.6–23.8) and histology (OR, 6.1, 95 percent CI, 3.5–10.6; p<0.0001) were all significant predictors of overtreatment with surgery.

The findings indicate that there is a need to exercise greater care before prescribing endoscopic submucosal dissection for EGC patients, said researchers. Employing additional diagnostic techniques could be helpful toward this end.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 3 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).